Endothelin-like pulmonary vasoconstrictor peptide release by a-thrombin ( endothelial celis / hemostasis / pulmonary circulation / HPLC / endothelial-derived constrictor factor )
D. Moon,M. Horgan,Thomas T. ANDERSENt,S. Krystek,J. Fenton,A. Malik
Abstract:The endothelial cells lining the vessel wall can modulate vasomotor tone by releasing vasoactive factors, such as endothelial-derived constricting factors. We observed that a-thrombin, but not catalytically inactivated a-thrombin, mediated the release of two pulmonary vasoconstrictor peptides into the venous effluent of guinea pig lungs. These peptides elicited a slow-onset, long-lasting pulmonary vasoconstriction similar to the effect of endothelin, an endothelial-derived 21-amino acid vasoconstrictor peptide previously isolated from cells in culture. One of the isolated peptides coelutes with endothelin upon reverse-phase HPLC with an acetonitrile gradient and has a molecular weight comparable to endothelin as determined by gel-permeation HPLC. The other vasoconstrictor peptide elutes earlier than endothelin on reverse-phase HPLC and exhibits a lower molecular weight. The studies show the release of endothelin-like pulmonary vasoconstrictor peptides in the intact lung by a-thrombin, a central regulatory enzyme in hemostasis. The vascular endothelium produces vasodilators, prostacyclin and the endothelial-derived relaxing factor (1, 2), and vasoconstrictors collectively termed endothelial-derived constrictor factors (EDCF) (3). One EDCF has been identified as endothelin, a 21-amino acid peptide initially isolated from cultured porcine aortic endothelial cells (4). Originally the human and porcine endothelins were found to have identical sequences (5), and the DNA sequence of the rat gene indicated 6 amino acid replacements in the aminoterminal half of the molecule (6). The two intrachain disulfide bonds and the hydrophobic carboxyl terminus [which appear necessary for the vasoconstrictor activity (7)] were conserved. More recently, three genes have been identified for endothelin in a human DNA library by Inoue et al. (8). These authors have suggested the nomenclature of ET-1 to designate the original porcine/human endothelin, ET-2, which has a Trp6,Leu7 substitution, and ET-3, the peptide initially designated as rat endothelin (8). Endothelin is released constitutively by cultured aortic endothelial cells (4). The endothelin-induced vasoconstriction is not inhibitied by a-adrenergic, cholinergic, histaminergic, and serotonergic antagonists (3, 4), nor by cyclooxygenase or lipoxygenase inhibitors (4). The vasoconstrictor response requires extracellular Ca2", is associated with increased intracellular free Ca2", and may be inhibited by dihydropyridine Ca2l channel antagonists (4, 9). A number of stimuli and vasoactive mediators such as thrombin, norepinephrine, or the Ca2l ionophore A23187 stimulate endothelin mRNA transcription in vitro (4). Endothelin may participate in hypertensive responses (10-13) because of its vasoconstrictor properties. However, whether endothelin or endothelin-like peptides are released in vivo is not known. In this study, we examined whether endothelin or endothelin-like peptides are released in the intact circulation. Studies were made in perfused guinea pig lungs challenged with athrombin, which we have shown to induce pulmonary vasoconstriction (14). MATERIALS AND METHODS Lungs were obtained from healthy Hartley guinea pigs of either sex (Buckberg, Tomkins Cove, NY) weighing 500 + 25 g (mean ± SEM), anesthetized with pentobarbital sodium (50 mg/kg, i.p., Abbott). The trachea was cannulated before opening the thorax. Heparin sodium (700 units/kg) was administered by intracardiac injection, and the animals were exsanguinated. The heart and lungs were carefully removed en bloc and suspended from one end of a beam balance (14). Catheters were placed in the pulmonary artery and left atrium. The lungs were covered with plastic wrap to reduce evaporative fluid loss. Perfusion of the system with a peristaltic pump (Harvard Apparatus, model 1215) was begun within 5 min of pneumothorax. The perfusate was a phosphate-buffered Ringer's solution containing 0.5% bovine albumin (fatty-acid-free, recrystallized, Sigma). The Ringer's solution contained 137 mM NaCI, 1.8 mM CaC12, 1.05 mM MgCl2, 2.68 mM KCI, 0.06 mM NaHCO3, 0.120 mM NaH2PO4, 0.869 mM Na2HPO4, and 5.55 mM dextrose. The perfusion rate was set at 28 ml/min in all experiments. Recirculation of the perfusate was begun after the venous effluent was clear of blood. Light microscopy of sample lungs indicated that they were essentially free of residual leukocytes and platelets (H. Lum and A.B.M., unpublished observations). The total perfusate volume was 300 ml. The lungs were suspended from a counterweighted beam balance with left atrial and pulmonary arterial pressure continuously measured with pressure transducers (Gould P50 and P23, respectively, Cleveland). Continuous recordings of the weight changes were made on a three-channel recorder (Gould model 2400S) to ensure that there was no pulmonary edema during the course of the experiment. Left atrial and airway pressures were adjusted to 3 and 1 cmH20, respectively, for all experiments. The lungs were continuously inflated with 95% 02/5% CO2. Three hundred milliliters ofpulmonary venous effluent was collected into a reservoir containing hirudin (20 nM final concentration) from either control (saline injection) or thrombin-treated (1 nM) lungs. A fresh (naive) lung was then prepared as described (14) and perfused with collected effluent. Complete inhibition of any thrombin not cleared by the Abbreviations: EDCF, endothelial-derived constrictor factors; PVF, pulmonary vasoconstrictor factor(s). 1To whom reprint requests should be addressed. 9529 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 9530 Medical Sciences: Moon et al. original lung was verified by testing an aliquot of the effluent for clotting activity using a fibrinometer (Becton Dickinson). Pulmonary venous effluent was collected from thrombinchallenged lungs and extracted with 2 vol of HPLC-grade diethyl ether (Burdick and Jackson). Most of the pulmonary vasoconstrictor factor(s) (PVF) activity localized at the ether/water interface, which was decanted, dried overnight on a Speed Vac (Savant), rehydrated in HPLC starting solvent (for HPLC analysis) or in Ringer's/albumin solution for injection into lungs (100 pil). Isocratic reverse-phase HPLC (15) was done on an Ultrex C18 (4.6 mm x 25 cm) purchased from Phenomenex (Belmont, CA). The mobile phase was 32% acetonitrile (Burdick and Jackson)/H20, pH 3.0 with phosphoric acid. Flow rate was 1 ml/min; ambient temperature and detection was at 203-nm absorbance. Gradient-elution reverse-phase HPLC was performed using a Zorbax C3 column (1.0 cm x 30 cm) (DuPont). The mobile phase was solvent A: 0.1% trifluoracetic acid (TFA)/ H20; solvent B: 0.1% TFA/acetonitrile. A linear gradient (0-60% acetonitrile) was generated over 40 min. Flow rate was 2.0 ml/min; ambient temperature and detection was at 215 nm. Amino acid analysis of the material detected in the HPLC peaks was done (16). Erhlich's reagent (17) was used to detect the presence of tryptophan. The material in the peaks was collected, dried to remove acetonitrile, resuspended in Ringer's/albumin solution, and injected into the pulmonary artery of naive lungs. Gel-permeation HPLC was performed by using a TSK-125 column with guard column (Bio-Rad) to determine molecular weights ofthe factors generated. The nominal Mr range ofthis column is 500-20,000 for proteins and peptides under denaturing conditions. The mobile phase was 0.10 M phosphate, pH 3.0 (with phosphoric acid) containing 5% dimethyl sulfoxide. The column was eluted isocratically at 0.7 ml/min; detection was at 259 nm. The column was calibrated, and a selectivity curve (distribution coefficient or Kay versus logarithm ofMr) was generated using cytochrome c, insulin, and glucagon (Sigma), and a series of peptides of known Mr values synthesized in our laboratory.